BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Antibody Drug Conjugates

Innovent Biologics Doses First Patient in Global Phase 1 Trial of IBI3020, a First-in-Class Dual-Payload CEACAM5 ADC

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment ...

April 30, 2025 | News

Keymed Biosciences Advances CDH17-Targeted ADC CM518D1 Into Phase I/II Trials for Solid Tumors in China

Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) develop...

April 28, 2025 | News

Akeso’s Ivonescimab Outperforms Pembrolizumab in Phase III, Wins NMPA Approval for First-Line PD-L1-Positive NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has re...

April 28, 2025 | News

Lotte Biologics Seals First ADC Manufacturing Deal to Launch Full-Scale US Production

Lotte Biologics has announced the signing of its first official contract manufacturing agreement at its newly expanded antibody-drug conjugate (ADC) produc...

April 25, 2025 | News

Sichuan Kelun-Biotech Secures FDA IND Clearance for First-in-Class ADC SKB518

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new dru...

April 22, 2025 | News

Nona Biosciences Partners with Atossa Therapeutics to Advance Next-Generation Antibody Therapies for Breast Cancer

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody ...

April 11, 2025 | News

Mabwell’s B7-H3-Targeting ADC 7MW3711 Enters Phase Ib/II Trial in China for Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) ha...

April 03, 2025 | News

Sichuan Kelun-Biotech Gets Green Light for First Radionuclide-Drug Conjugate Clinical Trial

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the invest...

March 26, 2025 | News

China’s Innovent Doses First Patient in Phase 3 Trial of HER2-Targeted ADC for Ovarian Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

March 25, 2025 | Report

Harbour BioMed and AstraZeneca Announce $4.6B Global Collaboration on Next-Gen Multi-Specific Antibodies

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody...

March 24, 2025 | News

Alphamab Oncology and CSPC’s Anti-HER2 ADC JSKN003 Secures Breakthrough Therapy Designation in China

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic...

March 19, 2025 | News

Pierre Fabre and RedRidge Bio Partner to Develop Biparatopic Antibody Drug Candidates

Pierre Fabre Laboratories and RedRidge Bio announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic...

March 13, 2025 | News

Navigating Biologics Development: Strategies for Regulatory Success, CMC Challenges, and Tech Transfer

Click here to Register Now! As the biologics field rapidly evolves, mastering regulatory pathways, process development, and tech transfer is essential for...

March 12, 2025 | News

WuXi XDC and AbTis Partner to Advance Site-Selective ADC Conjugation

WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiza...

March 12, 2025 | News

Stay Connected